Primary Medical Therapy for Acromegaly: An Open, Prospective, Multicenter Study of the Effects of Subcutaneous and Intramuscular Slow-Release Octreotide on Growth Hormone, Insulin-Like Growth Factor-I, and Tumor Size

S. Bevan, John; L. Atkin, Stephen; B. Atkinson, A.; Bouloux, P.-M.; Hanna, Fahmy; E. Harris, Philip; James, Roberta; V. McConnell, Michael; A. Roberts, G.; Scanlon, MF; M. Stewart, Paul; Teasdale, E.; Turner, Helen; Wass, John; M. Wardlaw, Joanna

doi:10.1210/jc.2001-012012

Public

Primary Medical Therapy for Acromegaly: An Open, Prospective, Multicenter Study of the Effects of Subcutaneous and Intramuscular Slow-Release Octreotide on Growth Hormone, Insulin-Like Growth Factor-I, and Tumor Size

Published in The Journal of Clinical Endocrinology & Metabolism • Oct 1, 2002

Authors:

John S. Bevan

Stephen L. Atkin

A. B. Atkinson

Abstract

Conventional surgery and radiotherapy for acromegaly have limitations. There are few data on the use of the somatostatin analog octreotide (Oct) as primary medical therapy. An open prospective study of 27 patients with newly diagnosed acromegaly was conducted in nine endocrine centers in the United ...

Subject

Acromegaly

Medicine

Octreotide

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!